Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00510107|
Recruitment Status : Unknown
Verified July 2007 by Gachon University Gil Medical Center.
Recruitment status was: Recruiting
First Posted : August 1, 2007
Last Update Posted : August 1, 2007
|Condition or disease||Intervention/treatment||Phase|
|Stomach Neoplasm Stage IV Recurrent||Drug: oxaliplatin Drug: Cisplatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase II Trial of Weekly Docetaxel/Cisplatin Versus Weekly Docetaxel/Oxaliplatin in Previously Untreated Patients With Advanced Gastric Cancer|
|Study Start Date :||July 2007|
|Estimated Study Completion Date :||July 2009|
Active Comparator: 1
Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
Cisplatin 60 mg/m2 will be given on day 1.
Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
oxaliplatin 120 mg/m2 will be given on day 1.
Other Name: Eloxatin
- response rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00510107
|Contact: Dong Bok Shin, MD, PhD||82 32 460 email@example.com|
|Korea, Republic of|
|Gachon University Gil Medical Center||Recruiting|
|Incheon, Korea, Republic of, 405 760|
|Principal Investigator:||Se Hoon Park, MD||Gachon University Gil Medical Center, Incheon, Korea|